Horizon Therapeutics acquires Viela Bio in a $3.05B Deal to expand its rare disease portfolio

“This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to accelerate our growth over the long term.” – Tim Walbert, Horizon Chief Executive Officer


Leave a Reply

Your email address will not be published. Required fields are marked *